Male Hypogonadism in Special Populations

What counts as hypogonadism, and why the same number means different things in different men

The Endocrine Society's clinical practice guideline on male hypogonadism defines the condition as a total testosterone below 300 ng/dL, confirmed on two separate morning blood draws, together with symptoms such as low libido, fatigue, depressed mood, or loss of muscle mass. That single laboratory threshold behaves very differently depending on who the patient is.

Organic (classical) hypogonadism comes from permanent damage to the hypothalamic-pituitary-gonadal axis: Klinefelter syndrome, pituitary tumors, bilateral orchiectomy, or gonadotoxic chemotherapy. Functional hypogonadism is reversible suppression of the same axis by a separate condition, most often obesity, poorly controlled diabetes, chronic opioid use, or acute illness. The distinction matters because functional hypogonadism can resolve when the driver is treated, while organic hypogonadism generally does not.

Assay variability, sex hormone-binding globulin (SHBG) changes, and acute illness can all shift a measured testosterone level, which is why the guideline requires two morning samples rather than one. Some laboratories and researchers use a lower cutoff, around 264 ng/dL, derived from harmonized assay data in healthy young men; using that lower threshold changes how many men are classified as hypogonadal. This is a real source of diagnostic disagreement, not a settled number, and clinicians should know which reference range their lab uses.

The Endocrine Society recommends against screening testosterone in asymptomatic men from the general population. It does support a lower threshold for testing in men with obesity, type 2 diabetes, chronic opioid use, HIV, or a history of gonadotoxic cancer treatment, because symptoms in these groups often overlap with the underlying condition itself and are easy to miss or misattribute.

What is established: the diagnostic criteria above, and the principle that functional causes should be identified and addressed before or alongside starting TRT. What is plausible but not settled: the exact prevalence figures reported for each special population vary across studies and cohorts, and some frequently cited percentages in the older literature have not been independently reconfirmed in this review. What is not established: a single testosterone cutoff or treatment algorithm that performs equally well across all of these populations; each one changes the pretest probability of a reversible cause and the risk-benefit balance of treatment.

Obesity and functional hypogonadism

Excess adipose tissue increases aromatase activity, which converts testosterone to estradiol and suppresses gonadotropin secretion through negative feedback at the hypothalamus. Obesity also lowers SHBG, so a total testosterone that looks borderline can still reflect a genuinely low free testosterone. Calculating free testosterone, or measuring it by equilibrium dialysis, adds useful precision in men with obesity rather than relying on total testosterone alone.

Weight loss is the first-line intervention for obesity-associated functional hypogonadism, and cohort data from long-running aging studies have linked meaningful weight loss to measurable increases in testosterone over time; bariatric surgery has been associated with even larger increases in pooled analyses. GLP-1 receptor agonists are increasingly used for weight management in this population, and testosterone increases have been observed in association with GLP-1-related weight loss. A 2026 systematic review following PRISMA methodology examined incretin-based therapies and testosterone outcomes in men with hypogonadism (PubMed); this is recent evidence, the underlying studies are heterogeneous, and it should be read as an emerging signal rather than a settled dose-response relationship.

The Endocrine Society guideline advises against starting testosterone therapy as the initial treatment for functional hypogonadism tied to obesity, metabolic syndrome, or type 2 diabetes, on the reasoning that lifestyle change or treatment of the underlying condition can normalize testosterone in many men. TRT is generally reserved for men whose testosterone remains low and symptomatic after a genuine attempt at weight loss, or for men in whom weight loss is not achievable and symptoms are significant.

Type 2 diabetes and the two-way relationship with testosterone

Biochemical hypogonadism is reported substantially more often in men with type 2 diabetes than in age-matched men without diabetes. The relationship appears bidirectional: low testosterone promotes insulin resistance and visceral fat gain, and insulin resistance in turn suppresses SHBG and gonadotropins, creating a cycle that reinforces itself. The American Diabetes Association's Standards of Care in Diabetes acknowledges this overlap and recommends testosterone measurement in men with type 2 diabetes who report symptoms of hypogonadism (2024 Standards of Care).

A large Australian randomized trial in men with impaired glucose tolerance or newly diagnosed type 2 diabetes and low-normal testosterone (known as T4DM) tested testosterone therapy against placebo, both added to a lifestyle program, and reported a meaningfully lower rate of progression to type 2 diabetes in the testosterone group over two years. This is genuinely notable because it is one of the only trials to test testosterone as a diabetes-prevention strategy rather than only a symptom treatment, but it does not establish that TRT is appropriate for glycemic control in men who already have established diabetes without confirmed hypogonadism.

For men with established type 2 diabetes and confirmed hypogonadism, a large cardiovascular safety trial of testosterone therapy (TRAVERSE) is the most relevant safety evidence available; it is discussed in the aging section below because its enrolled population skewed older and included substantial cardiovascular risk. Its finding of no increased cardiovascular event rate is relevant reassurance for men with diabetes, who carry elevated baseline cardiovascular risk, but TRAVERSE was not a diabetes-specific trial.

Improving glycemic control through standard means, including metformin, SGLT2 inhibitors, or GLP-1 receptor agonists, is commonly associated with testosterone increases independent of any testosterone prescription, and should be part of the initial approach before TRT in men whose diabetes is poorly controlled.

Chronic opioid therapy and androgen deficiency

Chronic opioid use suppresses the hypothalamic-pituitary-gonadal axis primarily at the hypothalamic level, reducing GnRH pulse frequency and producing a hypogonadotropic pattern: low or inappropriately normal LH and FSH alongside low testosterone. Opioid-induced androgen deficiency is common among men on long-term opioid therapy, with reported rates varying widely across studies depending on the specific opioid, dose, and route of administration; intrathecal opioids and high daily oral morphine-equivalent doses appear to carry the greatest risk. Buprenorphine, a partial opioid agonist, appears to cause less gonadal suppression than full agonists in the literature, and some clinicians consider it when preserving testosterone is a priority, though this is a clinical judgment rather than a guideline-mandated substitution.

Clinicians should measure morning total testosterone, along with LH and FSH, in men on chronic opioid therapy (generally defined as more than three months) who report sexual dysfunction, fatigue, or mood changes, to confirm a central mechanism rather than assume the diagnosis.

The preferred first step is opioid dose reduction or discontinuation when clinically appropriate and safe for pain control. For men who need to remain on opioids, testosterone replacement has been shown in a small randomized trial to improve sexual desire and erectile function over several months without increasing opioid requirements; this is useful but limited evidence from a modest sample size, and larger confirmatory trials would strengthen the recommendation.

One important limitation applies regardless of severity: TRT does not restore spermatogenesis, and in fact suppresses it further. Men with opioid-induced androgen deficiency who want to preserve or restore fertility should be referred to a reproductive endocrinologist to discuss options such as clomiphene citrate or hCG, which raise endogenous testosterone without shutting down sperm production the way exogenous testosterone does.

HIV infection and hypogonadism

Hypogonadism was very common among men with HIV before effective antiretroviral therapy existed and remains meaningfully more common today than in HIV-negative men of similar age, even with viral suppression. Mechanisms include chronic immune activation, lipodystrophy-related changes in body composition, direct viral effects on Leydig cells, and in some cases medications such as ketoconazole or megestrol acetate that suppress the hypothalamic-pituitary axis.

Low testosterone in men with HIV has been associated with accelerated loss of lean body mass, reduced bone mineral density, and lower quality of life, which is clinically important because sarcopenia independently predicts disability. An early placebo-controlled trial found that testosterone replacement improved lean body mass and quality of life in HIV-positive men with confirmed hypogonadism and weight loss, though this trial is decades old and reflects an earlier era of HIV treatment; contemporary confirmation with current antiretroviral regimens would strengthen confidence in the magnitude of benefit.

Monitoring in this group should include the standard TRT surveillance (hematocrit, PSA, lipids) plus attention to drug interactions, since some antiretroviral regimens affect hepatic metabolism of testosterone and SHBG can shift with regimen changes. Rechecking testosterone after any major antiretroviral switch is a reasonable practice.

Aging men

Testosterone declines gradually across adulthood, and the terms "late-onset hypogonadism" and "andropause" are used informally but are not formally endorsed diagnostic categories by major endocrine societies. A meaningful share of men over 60, and a larger share over 70, have total testosterone below the standard diagnostic threshold on testing.

The Testosterone Trials (TTrials) provide the strongest clinical evidence for hypogonadism treatment in older men, comprising coordinated placebo-controlled studies enrolling men aged 65 and older who had documented testosterone deficiency. Key outcomes from these trials showed modest gains in sexual function, which emerged as the most reliably observed benefit, along with slight increases in walking distance and spinal bone mineral density, though cognitive function and overall vitality showed minimal response to treatment.

The largest and most consequential recent trial in this space is TRAVERSE, a cardiovascular safety trial in men aged 45 to 80 with hypogonadism and existing or elevated cardiovascular risk. It reported no increased rate of major adverse cardiovascular events with testosterone therapy compared with placebo over roughly three years of follow-up, and a related substudy reported no significant increase in prostate cancer incidence or high-grade disease. This is genuinely reassuring evidence that has shifted clinical thinking away from cardiovascular concerns raised by older observational data, but the Endocrine Society still recommends individualized discussion, and long-term safety data beyond three to five years remain limited.

The practical diagnostic challenge in older men is separating true hypogonadism from the cumulative effects of obesity, diabetes, depression, and other comorbidities that can independently lower testosterone and cause similar symptoms. Managing those conditions first is reasonable before attributing symptoms to testosterone alone.

Chronic kidney disease and dialysis: an emerging area

Hypogonadism is common in men with advanced chronic kidney disease and those on hemodialysis, though this population has received less dedicated trial attention than obesity, diabetes, or aging. A 2026 study examined late-onset hypogonadism in male hemodialysis patients and its association with statin therapy and cholesterol levels (PubMed). This is a single, recent, observational study; it raises a plausible link between lipid-lowering therapy or cholesterol status and testosterone in dialysis patients, but it has not yet been replicated, and dialysis patients also carry cardiovascular and bone risks that complicate any TRT decision. Clinicians managing hypogonadism in dialysis patients should treat this as a developing area rather than an established treatment pathway, and should coordinate with the patient's nephrology team before starting TRT.

Cancer survivors and gonadotoxic therapy

The risk of permanent hypogonadism after cancer treatment depends heavily on the specific agent, cumulative dose, and radiation field. Alkylating chemotherapy agents (cyclophosphamide, procarbazine, busulfan) carry the highest risk of permanent Leydig cell damage, particularly in high-dose combination regimens used for conditions like Hodgkin lymphoma. Platinum-based regimens used for testicular cancer more often impair sperm production while leaving testosterone production relatively intact.

Testicular radiation above roughly 20 Gy can damage Leydig cells directly and cause permanent testosterone deficiency. At lower doses, sperm-producing cells are generally more radiosensitive than Leydig cells, so fertility loss commonly precedes testosterone deficiency rather than the reverse.

Screening is reasonable starting six to twelve months after completing gonadotoxic treatment, using morning total testosterone, LH, and FSH as a baseline. A pattern of elevated LH with borderline-low testosterone, sometimes called compensated hypogonadism, is common in survivors and can progress over years, which supports annual monitoring rather than a single post-treatment check.

TRT is generally considered acceptable in survivors of non-hormone-sensitive cancers once remission is confirmed, following the same principles as organic hypogonadism from any other cause. For survivors of prostate cancer specifically, published urology guidance describes TRT as something that may be offered to carefully selected men after counseling, based on observational data rather than large randomized trials; this remains a judgment call that should involve the treating oncologist or urologist, not a default decision.

Fertility preservation is a related but separate issue. Sperm banking before starting gonadotoxic therapy is the standard recommendation whenever fertility may matter to the patient. For men who present after treatment with azoospermia and preserved testosterone, testicular sperm extraction can retrieve viable sperm in a meaningful proportion of cases, though success depends heavily on which agent was used and at what dose.

Diagnosing hypogonadism across these populations

The diagnostic sequence is the same across populations, with population-specific additions layered on top.

Step one: measure total testosterone between roughly 7:00 and 10:00 AM on two separate days. Acute illness, recent hospitalization, and significant caloric restriction can all transiently suppress testosterone, so testing should be deferred until these have resolved when possible. Step two: if total testosterone is low, measure free testosterone (by equilibrium dialysis or calculated from total testosterone and SHBG), along with LH, FSH, and prolactin. Step three: use LH and FSH to distinguish primary (elevated LH/FSH, testicular) from secondary (low or normal LH/FSH, central) hypogonadism.

Population-specific additions:

• Obesity: calculate free testosterone; check estradiol
• Type 2 diabetes: check HbA1c; consider deferring TRT until glycemic control is optimized
• Chronic opioid use: confirm a central mechanism with LH/FSH; document current opioid dose and route
• HIV: review the antiretroviral regimen for interactions; check SHBG
• Older age: rule out pituitary pathology if prolactin is elevated or the pattern is clearly secondary
• CKD/dialysis: coordinate testing and interpretation with nephrology; consider lipid and statin status as a possible contributor
• Cancer survivors: obtain baseline LH/FSH and, if fertility matters to the patient, a semen analysis; schedule annual reassessment

A 2026 international expert consensus on managing testosterone deficiency in primary care (PubMed) reinforces the same core principle found in older guidelines: diagnosis should combine biochemistry with symptoms rather than treating a single number as decisive. A testosterone level of 280 ng/dL in an asymptomatic man does not, on its own, support treatment. A man with clear symptoms and a total testosterone of 310 ng/dL but a low free testosterone, due to low SHBG, may still be a reasonable candidate for further evaluation.

A decision framework for special populations

This is not a substitute for individualized clinical judgment or dosing decisions, but it summarizes the questions that should change what happens next.

The core rule: if a plausible reversible driver is present and has not yet been adequately treated, treat the driver first and retest in three to six months before starting TRT. If testosterone remains low and symptomatic after that, or if the hypogonadism is clearly organic (permanent testicular or pituitary damage, elevated LH/FSH from gonadotoxic therapy, or a structural cause), move to standard TRT contraindication screening and shared decision-making rather than continuing to wait.

Treatment selection and monitoring

TRT formulations include topical gels, intramuscular injections (such as testosterone cypionate or testosterone undecanoate), nasal gel, and subcutaneous pellets. No formulation has demonstrated clear superiority over the others in head-to-head comparisons; choice generally comes down to patient preference, cost, and insurance coverage, and should be discussed individually rather than defaulted to one option.

Before starting TRT, contraindications should be ruled out: a desire for fertility in the near term (TRT suppresses spermatogenesis), active breast or prostate cancer, a hematocrit above roughly 54%, untreated severe obstructive sleep apnea, or uncontrolled heart failure.

Reasonable monitoring includes checking testosterone around three months after starting (timing depends on formulation), then roughly every six to twelve months. Hematocrit should be checked at three months and then annually, with phlebotomy or dose reduction if it rises above the threshold noted above. PSA should be checked in the early months of treatment and then per age-appropriate screening guidelines. Bone density testing at one to two years is reasonable if osteoporosis was present at baseline.

For men with functional hypogonadism who want to preserve fertility, off-label clomiphene citrate or enclomiphene can raise endogenous testosterone while maintaining sperm production, an alternative worth discussing before defaulting to exogenous testosterone.

Any decision to start, continue, or stop TRT should follow shared decision-making, with symptoms reassessed at each visit. If a meaningful trial period of TRT (commonly discussed as around six months) produces no symptomatic improvement despite testosterone levels reaching a normal range, discontinuation is a reasonable option. When stopping, tapering the dose over several weeks allows time for hypothalamic-pituitary recovery, particularly in men whose hypogonadism was functional rather than organic.

When to seek care sooner rather than later

Most hypogonadism evaluation is not urgent, but certain findings warrant prompt medical attention rather than routine follow-up: signs of a pituitary mass (visual field changes, severe headache, other pituitary hormone abnormalities), very low testosterone with acute symptoms in a man on chronic opioids at a high dose, or new testicular pain or a mass, which should be evaluated directly rather than attributed to hypogonadism.

References

1. Endocrine Society. Clinical practice guideline on testosterone therapy in men with hypogonadism (2018). Referenced by name; the specific link accompanying this guideline in earlier drafts could not be independently verified in this review and has been removed. Editors should confirm the exact citation before publication.
2. American Diabetes Association. Standards of Care in Diabetes, 2024. https://diabetesjournals.org/care/article/47/Supplement_1/S1/153953/Standards-of-Care-in-Diabetes-2024
3. Effects of Incretin-Based Therapies on Testosterone Levels and Incretin Response in Men with Hypogonadism: A Systematic Literature Review Following PRISMA 2020 Guidelines (2026). https://pubmed.ncbi.nlm.nih.gov/42653816/
4. Late-Onset Hypogonadism in Male Hemodialysis Patients: Association with Statin Therapy and Cholesterol Levels (2026). https://pubmed.ncbi.nlm.nih.gov/42649028/
5. Managing testosterone deficiency in primary care: an international expert consensus (2026). https://pubmed.ncbi.nlm.nih.gov/42647144/

Note on sourcing: trials and studies named in the text above (including T4DM, TRAVERSE, the Testosterone Trials, STEP-1, and earlier randomized trials in HIV-associated and opioid-induced hypogonadism) are described qualitatively because the specific citation identifiers attached to them in the prior version of this article could not be verified against the correct source paper during this review. This draft is pending qualified medical and editorial review; exact citations, effect sizes, and any quoted statements should be confirmed against primary sources before publication.